

III. 研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
	なし						

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Furihata T, Fu Z, Suzuki Y, Matsumoto S, Morio H, Tsubota A, Matsumoto S, Chiba K.	Differential inhibition features of direct acting anti-hepatitis C virus agents against human organic anion transporting polypeptide 2B1.	Int J Antimicrob Agents		In press.	2015
Furihata T, Matsumoto S, Fu Z, Tsubota A, Sun Y, Matsumoto S, Kobayashi K, Chiba K.	Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides.	Antimicrob Agents Chemother	58(8)	4555-4564	2014
Panigrahi R, Chandra PK, Ferraris P, Kurt R, Song K, Garry RF, Reiss K, Coe IR, Furihata T, Balart LA, Wu T, Dash S.	Persistent hepatitis C virus infection impairs ribavirin antiviral activity through clathrin-mediated trafficking of equilibrative nucleoside transporter 1.	J Virol	89(1)	626-642	2014
Tsubota A, Mogushi K, Aizaki H, Miyaguchi K, Nagatsuma K, Matsudaira H, Kushida T, Furihata T, Tanaka H, Matsuura T.	Involvement of MAP3K8 and miR-17-5p in Poor Virologic Response to Interferon-Based Combination Therapy for Chronic Hepatitis C.	PLoS One	9(5)	e97078	2014
Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Itokawa N, Nakagawa A, Fukuda T, Matsushita Y, Nakatsuka K, Kawamoto C, Iwakiri K, Aizawa Y, Sakamoto C.	Safety and efficacy of partial splenic embolization in telaprevir-based triple therapy for chronic hepatitis C.	Intern Med	54(2)	119-126	2015
Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y.	Factors associated with sustained virological response in 24-week telaprevir-based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype.	Hepatol Res	45(4)	387-396	2015

Nakagawa A, Atsukawa M, Tsubota A, Shimada N, Abe H, Kondo C, Itokawa N, Arai T, Hashimoto S, Matsushita Y, Fukuda T, Nakatsuka K, Iwakiri K, Kawamoto C, Aizawa Y, Sakamoto C.	Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy.	Eur J Gastroenterol Hepatol	26(12)	1329-1334	2014
Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y.	Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients.	Gastroenterol Res Pract	2014	549709	2014
Masaki N, Sugiyama M, Shimada N, Tanaka Y, Nakamuta M, Izumi N, Watanabe S, Tsubota A, Komatsu M, Masaki T, Enomoto N, Yoneda M, Murata K, Ito K, Koike K, Mizokami M.	Pretreatment prediction of the outcome of response-guided peginterferon- and ribavirin therapy for chronic hepatitis C.	J Gastroenterol Hepatol	29(12)	1996-2005	2014
Atsukawa M, Tsubota A, Shimada N, Abe H, Kondo C, Itokawa N, Nakagawa A, Iwakiri K, Kawamoto C, Aizawa Y, Sakamoto C.	Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C.	Dig Liver Dis	46(8)	738-743	2014
Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Fukuda T, Matsushita Y, Narahara Y, Osada Y, Yamaguchi H, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C.	Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C.	Eur J Gastroenterol Hepatol	26(7)	781-787	2014
Shimada N, Tsubota A, Atsukawa M, Abe H, Ide T, Takaguchi K, Chuganji Y, Toyoda H, Yoshizawa K, Ika M, Sato Y, Kato K, Kumada T, Sakamoto C, Aizawa Y, Sata M.	A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study.	Hepatol Res	44(14)	E386-396.	2014

<p>Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Narahara Y, Iwakiri K, Nakatsuka K, Kawamoto C, Sakamoto C.</p>	<p>Serum 25-hydroxyvitamin D3 levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load.</p>	<p>Hepatol Res</p>	<p>44(13)</p>	<p>1277-1285</p>	<p>2014</p>
<p>Shimada N, Toyoda H, Tsubota A, Ide T, Takaguchi K, Kato K, Kondoh M, Matsuyama K, Kumada T, Sata M.</p>	<p>Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.</p>	<p>J Gastroenterol</p>	<p>49(11)</p>	<p>1485-1494</p>	<p>2014</p>